Barinthus Biotherapeutics (NASDAQ:BRNS) has entered into a proposed all-stock business combination with Clywedog, a strategic move aimed at consolidating resources and advancing a diversified immunotherapy pipeline.
The transaction is expected to close in the second quarter of 2026, after which the combined company will begin trading on the Nasdaq under the new ticker symbol CLYD.
The merger announcement accompanied Barinthus Bio’s full-year 2025 financial results, which showed the company maintained a solid capital base of $71.9 million in cash and cash equivalents as of December 31, 2025.
Management estimates that this liquidity, combined with the efficiencies gained from the merger, provides an operational runway through 2027, covering several critical clinical milestones.
A primary focus for the upcoming year remains the development of VTP-1000, the company’s lead candidate designed to treat chronic infectious diseases and autoimmunity.
Barinthus reported that single ascending dose (SAD) data for VTP-1000 has already demonstrated a favorable tolerability profile and successful pharmacodynamic T cell recognition.
The company is now progressing toward multiple ascending dose (MAD) data from its Phase 1 trial, which is expected to be released in the second half of 2026.
The combined entity plans to leverage its expanded platform to accelerate clinical recruitment and broaden its reach in the T cell-mediated therapy space.